Search Results 451-460 of 16654 for pharmacogenetics
Endothelial dysfunction appears to be caused by both sleep disordered breathing and obesity. As endothelial dysfunction is among the first clinical marker that ...
Review the focus areas, mentors and publications of current and former trainees in the Clinical Pharmacology Training Program at Mayo Clinic.
These patients are at high risk for progression of kidney disease, which can result in end-stage renal failure. Participation eligibility. Participant ...
The key outcomes in the study focus on evaluation of clinical remission, defined as Birmingham Vasculitis Activity Score (BVAS)=0 with a corticosteroid dose of ...
Subjects must not be eligible for therapy of higher curative potential where an alternative treatment has been shown to prolong survival in an analogous ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Romidepsin and lenalidomide may stop the growth ...
Researchers in this brain focus area of the Discovery and Translation Labs at Mayo Clinic focus on translational research related to biomarker and drug ...
PHOENIX — Current genetic screening guidelines fail to identify most people with an inherited condition known as familial hypercholesterolemia that can ...
ROCHESTER, Minn. — At Mayo Clinic, cardiologists Peter Noseworthy, M.D., and John Giudicessi, M.D., Ph.D., are uncovering the earliest signs of a genetic heart ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift can go 3X as far to shape the future of cancer care.